[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"PeriPharm\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":89},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,61],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100617805","real-world-study-on-the-impact-of-atopic-dermatitis-from-a-caregiver-perspective-100617805",false,"NCT07323394","Real-World Study on the Impact of Atopic Dermatitis From a Caregiver Perspective","Inclusion Criteria:\n\n1. Aged ≥18 years;\n2. Caregiver of a child aged ≥2 to ≤11 years with mild to moderate atopic dermatitis;\n3. Able to read and understand French or English;\n4. Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n1. Caregivers whose child has been diagnosed with severe atopic dermatitis ;\n2. Caregivers whose child is currently treated with oral or topical Janus Kinase Inhibitor);\n3. Caregivers whose child is currently participating in a clinical trial for atopic dermatitis;\n4. Other parent or caregiver within the household of the child with atopic dermatitis.",true,"ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","OBSERVATIONAL","This study will address this gap by providing comprehensive data on disease burden from a caregiver perspective in a Canadian population, ultimately supporting improved clinical decision-making and healthcare resource allocation.",[24,25,26,27,28],"Atopic Dermatitis","Eczema Atopic Dermatitis","Eczema","Caregiver","Burden",[30,31,32],"atopic dermatitis","quality of life","real-world","NOT_YET_RECRUITING","2026-01-22",{"date":36,"type":37},"2026-01-23","ACTUAL",{"date":39,"type":20},"2026-01",{"date":41,"type":20},"2026-07",{"name":43,"class":44},"PeriPharm","OTHER",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":59,"leadSponsor":60,"locationsCount":4},"100617798","real-world-study-on-the-burden-of-hidradenitis-suppurativa-100617798","NCT07323303","Real-World Study on the Burden of Hidradenitis Suppurativa","Inclusion Criteria:\n\n1. Patient diagnosed with HS;\n2. Aged ≥18 years;\n3. Able to read and understand French or English;\n4. Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n1\\. Participation in an interventional study for HS.",{"count":19,"type":20},"Despite the significant impact of HS on patients' quality of life (QoL) and daily functioning, there remains limited real-world evidence describing the burden of this condition in Canada. HS is an under-recognized and often misdiagnosed condition, with a substantial psychological and physical burden on patients. Understanding the real-world experiences of individuals living with HS in Canada can help identify unmet needs and inform patient-centered care approaches.",[54],"Hidradenitis Suppurativa (HS)","2025-12-22",{"date":57,"type":37},"2026-01-07",{"date":39,"type":20},{"date":41,"type":20},{"name":43,"class":44},{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":69,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":70,"conditions":71,"keywords":76,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},"100576502","societal-burden-associated-with-type-1-diabetes-in-canada-100576502","NCT06786130","Societal Burden Associated With Type 1 Diabetes in Canada","Burden and (Dis)Utility of Caregivers of Children With T1D","T1D","Inclusion Criteria:\n\n1. Parental caregiver of a child recently diagnosed (\\\u003C= 2 years) with T1D before study inclusion;\n2. Age ≥18 ;\n3. Residence in the Canada;\n4. Willingess to complete a 20-minute survey\n5. Ability to read and understand French or English;\n6. Signature of informed consent form (ICF)\n\nExclusion Criteria:\n\n1\\. Participation in a clinical trial.",{"count":19,"type":20},"The purpose of this observational study is to estimate the burden of T1D on caregivers of patient with T1D in terms of work productivity, healthcare resource utilization and quality of life.",[72,73,74,75],"Type 1 Diabetes Mellitus","Quality of Life (QOL)","Work Productivity","Caregiver Subjective Burden",[77,31,78,79,32],"observational","caregiver","work productivity","RECRUITING",{"date":82,"type":37},"2025-12-23",{"date":84,"type":37},"2025-01-09",{"date":86,"type":20},"2025-12",{"name":43,"class":44},1,""]